Authors: Stone JH, Frigault MJ, Sterling-Boyd NJ, Fernandes AD, Harvey FL PMID: 33085857 PMCID: PMC7646626 DOI: 10.1056/NEJMoa2028836 Abstract Background: The efficacy of interleukin-6 receptor blockade in hospitalized patients with coronavirus disease 2019 (Covid-19) who are not receiving mechanical ventilation is unclear. Methods: We performed a randomized, double-blind, placebo-controlled trial involving patients with confirmed severe acute [...]

Authors: Valizadeh H, Danshina S, Gencer MZ, Ammari A, Sadeghi A, Aslani S. PMID: PMC7574843 DOI: 10.1016/j.intimp.2020.107088 Abstract Background: As an ongoing worldwide health issue, Coronavirus disease 2019 (COVID-19) has been causing serious complications, including pneumonia, acute respiratory distress syndrome (ARDS), and multi-organ failure. However, there is no decisive treatment approach available for this disorder, [...]

Authors: Yeramaneni S, Doshi P, Sands K, Cooper M, Kurbegov D, Fromell G PMID: 33058865 PMCID: PMC7550093 doi: 10.1053/j.gastro.2020.10.011 Abstract Previous reports have found that in-hospital famotidine use in coronavirus disease 2019 (COVID-19) patients was associated with reduced risk of death or intubation.1 , 2 In 1 of these studies the authors proposed that famotidine [...]

Authors: Villa G, Romagnoli S, De Rosa S, Greco M, Resta M PMID: 33046113 PMCID: PMC7549343 DOI: 10.1186/s13054-020-03322-6 Abstract Background: Systemic inflammation in COVID-19 often leads to multiple organ failure, including acute kidney injury (AKI). Renal replacement therapy (RRT) in combination with sequential extracorporeal blood purification therapies (EBP) might support renal function, attenuate systemic inflammation, [...]

Authors: Mather JF, Seip RL, McKay RG PMID: 32852338 PMCID: PMC7473796 DOI: 10.14309/ajg.0000000000000832 Abstract Introduction: To compare outcomes in patients hospitalized with coronavirus (COVID-19) receiving famotidine therapy with those not receiving famotidine. Methods: Retrospective, propensity-matched observational study of consecutive COVID-19-positive patients between February 24, 2020, and May 13, 2020. Results: Of 878 patients in the [...]

Authors: Chamie J Abstract In these eight Peruvian State analyses, Ivermectin distributions preceded sound reductions in excess deaths and case fatality rate (CFR). The variation in the number of detected cases nor the vulnerable population decrease can explain this reduction. Other possible explanations, such as cross-immunity with dengue, or mere causality, have been discarded due [...]

Authors: Derosa G, Maffioli P, D'Angelo A, Di Pierro F PMID: 33034398 PMCID: PMC7675685 DOI: 10.1002/ptr.6887 Abstract Several months ago, an outbreak of pneumonia of unknown aetiology was detected in Wuhan City (China) and the aetiological agent of the atypical pneumonia was isolated by the Chinese authorities as novel coronavirus (2019-nCoV or SARS-CoV-2). The WHO [...]

Authors: Rawson TM, Wilson RC, Holmes A PMID: 32979569 PMCID: PMC7546203 DOI: 10.1016/j.cmi.2020.09.025 Abstract The novel coronavirus disease (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has placed an unprecedented strain on healthcare systems. An emerging concern is the potential impact of the novel coronavirus SARS-CoV-2 pandemic on antimicrobial resistance (AMR). [...]

Authors: Dequin PF, Heming N, Meziani F, Plantefeve G, Voiriot G PMID: 32876689 PMCID: PMC7489432 DOI: 10.1001/jama.2020.16761 Abstract Importance: Coronavirus disease 2019 (COVID-19) is associated with severe lung damage. Corticosteroids are a possible therapeutic option. Objective: To determine the effect of hydrocortisone on treatment failure on day 21 in critically ill patients with severe acute [...]

Authors: Angus DC, Derde L, Al-Beidh F, Annane D, Arabi Y, et al. PMID: 32876697 PMCID: PMC7489418 DOI: 10.1001/jama.2020.17022 Abstract Importance: Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. Objective: To determine whether hydrocortisone improves outcome for patients with severe COVID-19. Design, setting, and participants: An ongoing adaptive platform trial testing [...]